SCHEMBL2020684

SCHEMBL2020684

O=C(Nc1ccc(N2CCCCC2)cc1)c1cccc(Nc2ncnc3[nH]cc(C(=O)c4ccccc4)c23)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 9/20 0.53
NPC1 O15118 9/20 0.51
RAB9A P51151 9/20 0.51
MAPT P10636 7/20 0.51
SMN1; SMN2 Q16637 6/20 0.51
TP53 P04637 3/20 0.51
PKM P14618 3/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
TSHR P16473 1/20 0.47
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ALDH1A1 P00352 3/20 0.45
QSOX1 O00391 1/20 0.45
LMNA P02545 1/20 0.45
POLB P06746 1/20 0.45
MCL1 Q07820 1/20 0.45
USP2 O75604 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2024268 0.93 BTK (0.54) BTKRAB9AMAPTSMN1; SMN2TP53
SCHEMBL2019641 0.89 BTK (0.60) BTK
SCHEMBL2022435 0.88 TSHR (0.49) BTKMAPTSMN1; SMN2TSHRMEN1
SCHEMBL2024249 0.85 BTK (0.55) BTKMEN1KMT2A
SCHEMBL2018946 0.85 BTK (0.55) BTKNPC1RAB9AMEN1KMT2A
SCHEMBL2019583 0.83 BTK (0.52) BTK
SCHEMBL12490856 0.83 BTK (0.59) BTK
SCHEMBL12495300 0.82 AURKB (0.61) BTKNPC1RAB9AMEN1KMT2A
SCHEMBL2027637 0.81 SCN9A (0.55) BTKNPC1MAPTSMN1; SMN2TSHR
SCHEMBL2018889 0.81 BTK (0.54) BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580803-B2 Substituted pyrrolo-aminopyrimidine compounds ARQULE, INC. (US) 2013-11-12 US disclosed
US-8580803-B2 Substituted pyrrolo-aminopyrimidine compounds ARQULE, INC. (US) 2013-11-12 US disclosed
US-8580803-B2 Substituted pyrrolo-aminopyrimidine compounds ARQULE, INC. (US) 2013-11-12 US disclosed
WO-2011082273-A2 SUBSTITUTED PYRROLO-AMINOPYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2011-07-07 WO disclosed
US-20110160203-A1 Substituted Pyrrolo-Aminopyrimidine Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160203-A1 Substituted Pyrrolo-Aminopyrimidine Compounds ARQULE, INC. (US) 2011-06-30 US disclosed
US-20110160203-A1 Substituted Pyrrolo-Aminopyrimidine Compounds ARQULE, INC. (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160203-A1 Substituted Pyrrolo-Aminopyrimidine Compounds DPYD, TYMP, DHFR BTK 1600/4885NPC1 2886/4885RAB9A 2955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.